Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jun 2025 According to a Bial media release, the study has enrolled 273 genetically confirmed GBA-PD patients, several of whom have already completed the trial, across 85 sites in Europe and North America. Topline data from this trial is expected in the second quarter of 2026.
02 Jun 2025 According to a Bial media release, data from this trial will be presented at the GBA1 Meeting 2025 being held June 5-7, 2025.
07 Jan 2025 According to a Bial media release, Topline data from this Phase 2 study is expected to be released in mid-2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com